About this document
HSIE Results Daily: February 2024 Insights by adityazade03 is a document available to read on EtoBox.
- Zydus Lifesciences reported steady sales growth in Q3 led by growth in India (+16% YoY) and emerging markets (+31% YoY), while US sales were muted. Higher gross margins and lower SG&A/R&D expenses led to 28% EBITDA growth. - For FY24, Zydus expects double-digit revenue growth and operating margins of around 27%. It sees margins sustaining above 24% in FY25 if there is no new competition for its product gAsacol HD. - The brokerage maintains a
- Author
- adityazade03
- Language
- EN